Nyxoah SA Retained Earnings (Accumulated Deficit) 2021-2024 | NYXH

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Nyxoah SA retained earnings (accumulated deficit) from 2021 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Nyxoah SA Retained Earnings (Accumulated Deficit) 2021-2024 | NYXH

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Related Stocks
Company Name	Market Cap
GE HealthCare Technologies (GEHC)	$40.4B
Tempus AI (TEM)	$7.9B
Inspire Medical Systems (INSP)	$6.2B
Axonics (AXNX)	$3.5B
Hims & Hers Health (HIMS)	$3.5B
10x Genomics (TXG)	$2.7B
Enovis (ENOV)	$2.4B
Azenta (AZTA)	$2.4B
Privia Health (PRVA)	$2.3B
IRhythm Technologies (IRTC)	$2.2B
Omnicell (OMCL)	$2B
Clover Health Investments (CLOV)	$1.5B
Schrodinger (SDGR)	$1.4B
Phreesia (PHR)	$1.4B
Standard BioTools (LAB)	$753M
Fulgent Genetics (FLGT)	$694M
Definitive Healthcare (DH)	$538M
Health Catalyst (HCAT)	$529M
Butterfly Network (BFLY)	$406M
Talkspace (TALK)	$343M
Pulmonx (LUNG)	$329M
SOPHiA GENETICS SA (SOPH)	$286M
TruBridge (TBRG)	$183M
P3 Health Partners (PIII)	$165M
American Well (AMWL)	$147M
Augmedix (AUGX)	$115M
EUDA Health Holdings (EUDA)	$90M
Future Health ESG (FHLT)	$65M
SHL Telemedicine (SHLT)	$55M
HeartBeam (BEAT)	$53M